Survivin Signaling in Clinical Oncology: A Multifaceted Dragon

Medicinal Research Reviews

Volumn 33, Issue 4, 2013, Pages 765-789

  Kanwar, Jagat R ^a   Kamalapuram, Sishir K ^a   Kanwar, Rupinder K ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

Angiogenesis; Cancer; Cell signaling; Diagnosis; Prognosis; Survivin; Treatment

Indexed keywords

CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CYCLOPHOSPHAMIDE; DIMETHYLBENZ[A]ANTHRACENE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; GATAPARSEN; HEAT SHOCK PROTEIN 90; HLA ANTIGEN CLASS 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE; OXALIPLATIN; PACLITAXEL; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; SEPANTRONIUM BROMIDE; STAT PROTEIN; SURVIVIN; TOLFENAMIC ACID; TRASTUZUMAB; UNINDEXED DRUG; VASCULOTROPIN;

ADENOCARCINOMA; ARTICLE; BLADDER CANCER; BRAIN CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; COLORECTAL CANCER; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; GENE EXPRESSION PROFILING; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; LUNG CANCER; MESOTHELIOMA; MOUTH CANCER; NASOPHARYNX CANCER; OVARY CANCER; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN CANCER; STOMACH CANCER; TRANSITIONAL CELL CARCINOMA; ULTRAVIOLET IRRADIATION; WESTERN BLOTTING;

ANIMALS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84878656499     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21264     Document Type: Article

References (103)

1. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: The cell-signalling perspective. Drug Discov Today 2011;16(11-12):485-494.
2. Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008;8(1):61-70.
3. Altieri DC. New wirings in the survivin networks. Oncogene 2008;27(48):6276-6284.
4. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001;93(20):1541-1552.
5. Kanwar RK, Cheung CH, Chang JY, Kanwar JR. Recent advances in anti-survivin treatments for cancer. Curr Med Chem 2010;17(15):1509-1515.
6. Kanwar JR, Kamalapuram SK, Kanwar RK. Targeting survivin in cancer: Patent review. Expert Opin Ther Pat 2010;20(12):1723-1737.
7. Kanwar JR. Gataparsen, an antisense oligonucleotide targeting survivin for cancer. Thomson Reuters Pharma 2011.
8. Kanwar JR, Singh N, Kanwar RK. Role of nanomedicine in reversing drug resistance mediated by ATP binding cassette transporters and P-glycoprotein in melanoma. Nanomedicine 2011;6(4):701-714.
9. Baratchi S, Kanwar RK, Cheung CH, Kanwar JR. Proliferative and protective effects of SurR9-C84A on differentiated neural cells. J Neuroimmunol 2010;227(1-2):120-132.
10. Baratchi S, Kanwar RK, Kanwar JR. Survivin: A target from brain cancer to neurodegenerative disease. Crit Rev Biochem Mol Biol 2010;45(6):535-554.
11. Krissansen GW, Sun X, Kanwar JR. Tumor treating combinations, compositions and methods. United States. 2005. Pub No: WO/2004/009131.
12. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004;114(8):1117-1127.
13. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: Fulfilled promises and open questions. Carcinogenesis 2007;28(6):1133-1139.
14. Kanwar JR, Mahidhara G, Kanwar RK. Recent advances in nanoneurology for drug delivery to the brain. Curr Nanosci 2009;5(4):441-448.
15. Kanwar JR, Mahidhara G, Kanwar RK. Antiangiogenic therapy using nanotechnological-based delivery system. Drug Discov Today 2011;16(5-6):188-202.
16. Baratchi S, Kanwar RK, Khoshmanesh K, Vasu P, Ashok C, Hittu M, Parratt A, Krishnakumar S, Sun XY, Sahoo SK, Kanwar JR. Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases. Curr Nanosci 2009;5(1):15-25.
17. Summers H. Bionanoscience: Nanoparticles in the life of a cell. Nat Nanotechnol 2011;7(1):9-10.
18. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I, Nokisalmi P, Raki M, Rajecki M, Guse K, Ranki T, Oksanen M, Holm S-L, Haavisto E, Karioja-Kallio A, Laasonen L, Partanen K, Ugolini M, Helminen A, Karli E, Hannuksela P, Pesonen S, Joensuu T, Kanerva A, Hemminki A. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010;18(10):1874-1884.
19. Lee J, Kang WK, Park JO, Park SH, Park YS, Lim HY, Kim J, Kong J, Choi MG, Sohn TS, Noh JH, Bae JM, Kim S, Lim DH, Kim K-M, Park CK. Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS 2009;117(8):598-606.
20. Ko YH, Roh SY, Won HS, Jeon EK, Hong SH, Lee MA, Kang JH, Hong YS, Kim MS, Jung CK. Prognostic significance of nuclear survivin expression in resected adenoid cystic carcinoma of the head and neck. Head Neck Oncol 2010;2:30.
21. Chen X, Luo S, Li N, Song Y, Zen J. Relationship between the expression of ERCC-1, survivin and both efficiency and prognosis of cisplatin contained first-line chemotherapy in advanced lung adenocarcinoma. Chin-German J Clin Oncol 2009;8(5):265-268.
22. Vallböhmer D, Peters JH, Oh D, Kuramochi H, Shimizu D, DeMeester SR, Hagen JA, Chandrasoma PT, Danenberg KD, DeMeester TR, Danenberg P. Survivin, a potential biomarker in the development of barrett's adenocarcinoma. Surgery 2005;138(4):701-707.
23. Birkhahn M, Mitra AP, Williams AJ, Lam G, Ye W, Datar RH, Balic M, Groshen S, Steven KE, Cote RJ. Predicting recurrence and progression of noninvasive papillary bladder cancer at initial presentation based on quantitative gene expression profiles. European Urology 2010;57(1):12-20.
24. Als AB, Dyrskjot L, von der Maase H, Koed K, Mansilla F, Toldbod HE, Jensen JL, Ulhoi BP, Sengelov L, Jensen KM, Orntoft TF. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res 2007;13(15 Pt 1):4407-4414.
25. Atlasi Y, Mowla SJ, Ziaee SAM. Differential expression of survivin and its splice variants, survivin-Delta Ex3 and survivin-2B, in bladder cancer. Cancer Detect Prev 2009;32(4):308-313.
26. Gonzalez S, Aubert S, Kerdraon O, Haddad O, Fantoni JC, Biserte J, Leroy X. Prognostic value of combined p53 and survivin in pT1G3 urothelial carcinoma of the bladder. Am J Clin Pathol 2008;129(2):232-237.
27. Zhao J, Wang ZQ, Wang XY, Yang XJ, He D. Preliminary study of diagnostic utility of molecular beacons in bladder cancer. Urology 2010;76(2):512 e518-513.
28. Pu XY, Wang ZP, Chen YR, Wang XH, Wu YL, Wang HP. The value of combined use of survivin, cytokeratin 20 and mucin 7 mRNA for bladder cancer detection in voided urine. J Cancer Res Clin 2008;134(6):659-665.
29. Ziaee SA, Moula SJ, Hosseini Moghaddam SM, Eskandar-Shiri D. Diagnosis of bladder cancer by urine survivin, an inhibitor of apoptosis: A preliminary report. Urol J 2006;3(3):150-153.
30. Horstmann M, Bontrup H, Hennenlotter J, Taeger D, Weber A, Pesch B, Feil G, Patschan O, Johnen G, Stenzl A, Bruning T. Clinical experience with survivin as a biomarker for urothelial bladder cancer. World J Urol 2010;28(3):399-404.
31. Eissa S, Swellam M, Shehata H, El-Khouly IM, El-Zayat T, El-Ahmady O. Expression of HYAL1 and survivin RNA as diagnostic molecular markers for bladder cancer. J Urol 2010;183(2):493-498.
32. Dogu GG, Ozkan M, Ozturk F, Dikilitas M, Er O, Ozturk A. Triple-negative breast cancer: Immunohistochemical correlation with basaloid markers and prognostic value of survivin. Med Oncol 2010;27(1):34-39.
33. Lu XW, Gu YM, Zhu DL, Tan JX, Liu XR, Zha XM. Promoter methylation status of PTEN, SYK and survivin genes in breast cancer tissues derived from Chinese women. Asian Biomed 2009;3(6):595-601.
34. Toi M, Iwata H, Fujiwara Y, Ito Y, Nakamura S, Tokuda Y, Taguchi T, Rai Y, Aogi K, Arai T, Watanabe J, Wakamatsu T, Katsura K, Ellis CE, Gagnon RC, Allen KE, Sasaki Y, Takashima S. Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: Efficacy, safety, and biomarker results from Japanese patients phase II studies. Br J Cancer 2009;101(10):1676-1682.
35. Lanigan F, Gremel G, Hughes R, Brennan DJ, Martin F, Jirstrom K, Gallagher WM. Homeobox transcription factor muscle segment homeobox 2 (Msx2) correlates with good prognosis in breast cancer patients and induces apoptosis in vitro. Breast Cancer Res 2010;12(4):R59.
36. Vazquez-Martin A, Oliveras-Ferraros C, del Barco S, Martin-Castillo B, Menendez JA. The antidiabetic drug metformin: A pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy. Ann Oncol 2009;20(3):592-595.
37. Brennan DJ, Rexhepaj E, O'Brien SL, McSherry E, O'Connor DP, Fagan A, Culhane AC, Higgins DG, Jirstrom K, Millikan RC, Landberg G, Duffy MJ, Hewitt SM, Gallagher WM. Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer. Clin Cancer Res 2008;14(9):2681-2689.
38. Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, Zhang MF, Wan DS. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis 2009;24(8):875-884.
39. Gazouli M, Tzanakis N, Rallis G, Theodoropoulos G, Papaconstantinou I, Kostakis A, Anagnou NP, Nikiteas N. Survivin -31G/C promoter polymorphism and sporadic colorectal cancer. Int J Colorectal Dis 2009;24(2):145-150.
40. Li J, He W, He Y. The prediction of recurrence and survival of patients with dukes' B colorectal cancer after curative resection with immunohistochemical detection of survivin and livin expressions. The Chinese-German Journal of Clinical Oncology 2008;7(1):22-26.
41. Soreide K, Gudlaugsson E, Skaland I, Janssen EA, Van Diermen B, Korner H, Baak JP. Metachronous cancer development in patients with sporadic colorectal adenomas-multivariate risk model with independent and combined value of hTERT and survivin. Int J Colorectal Dis 2008;23(4):389-400.
42. Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. The Lancet 2003;362(9379):205-209.
43. Zhang T, Fields JZ, Opdenaker L, Otevrel T, Masuda E, Palazzo JP, Isenberg GA, Goldstein SD, Brand M, Boman BM. Survivin-induced aurora-B kinase activation a mechanism by which APC mutations contribute to increased mitoses during colon cancer development. Am J Pathol 2010;177(6):2816-2826.
44. Sawai K, Goi T, Hirono Y, Katayama K, Yamaguchi A. Survivin-3B gene decreases the invasion-inhibitory effect of colon cancer cells with 5-fluorouracil. Oncol Res 2010;18(11-12):541-547.
45. Dellas K, Roedel F, Arnold D, Kappler M, Hipp M, Bataille F, Vordermark D, Roedel C, Hartmann A. EGFR, PTEN, and survivin expression in pre- and posttherapeutic specimens does not predict a clinical benefit from preoperative chemoradiation with cetuximab in patients (pts) with locally advanced rectal cancer (LARC). J Clin Oncol 2010;28(15):3653.
46. Deng JY, Sun D, Liu XY, Pan Y, Liang H. STAT-3 correlates with lymph node metastasis and cell survival in gastric cancer. World J Gastroenterol 2010;16(42):5380-5387.
47. Bertazza L, Mocellin S, Marchet A, Pilati P, Gabrieli J, Scalerta R, Nitti D. Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival. J Transl Med 2009;7:111.
48. Wu YK, Chen KT, Kuo YB, Huang YS, Chan EC. Quantitative detection of survivin in malignant pleural effusion for the diagnosis and prognosis of lung cancer. Cancer Lett 2009;273(2):331-335.
49. Yie SM, Lou B, Ye SR, He X, Cao M, Xie K, Ye NY, Lin R, Wu SM, Xiao HB, Gao E. Clinical significance of detecting survivin-expressing circulating cancer cells in patients with non-small cell lung cancer. Lung Cancer 2009;63(2):284-290.
50. Rom W, Goldberg J, Addrizzo-Harris D, Watson H, Khilkin M, Greenberg A, Naidich D, Crawford B, Eylers E, Liu D, Tan E. Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. BMC Cancer 2010;10(1):234.
51. Nakano J, Huang C, Liu D, Masuya D, Yokomise H, Ueno M, Haba R, Sumitomo S. The clinical significance of splice variants and subcellular localisation of survivin in non-small cell lung cancers. Br J Cancer 2008;98(6):1109-1117.
52. Farlow EC, Patel K, Basu S, Lee BS, Kim AW, Coon JS, Faber LP, Bonomi P, Liptay MJ, Borgia JA. Development of a multiplexed tumor-associated autoantibody-based blood test for the detection of non-small cell lung cancer. Clin Cancer Res 2010;16(13):3452-3462.
53. Grinberg-Rashi H, Ofek E, Perelman M, Skarda J, Yaron P, Hajdúch M, Jacob-Hirsch J, Amariglio N, Krupsky M, Simansky DA, Ram Z, Pfeffer R, Galernter I, Steinberg DM, Ben-Dov I, Rechavi G, Izraeli S. The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin Cancer Res 2009;15(5):1755-1761.
54. DongXia Yang, NaiE Li, Yun Ma, YanChun Han, Shi Y. Expression of Elf1 and survivin in nonsmall cell lung cancer and their relationship to intratumoral microvessel density. Chin J Cancer 2009;29(4):396-402.
55. Chen G, Wang X, Liu Y, Wang L, Yang H, Duan H. Expressions of FEZ1 and survivin, and their significance in small cell lung cancer and squamous cell lung carcinoma. Chin-German J Clin Oncol 2008;7(4):207-209.
56. Ezponda T, Pajares MJ, Agorreta J, Echeveste JI, López-Picazo JM, Torre W, Pio R, Montuenga LM. The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression. Clin Cancer Res 2010;16(16):4113-4125.
57. Carrasco RA, Stamm NB, Marcusson E, Sandusky G, Iversen P, Patel BKR. Antisense inhibition of survivin expression as a cancer therapeutic. Mol Cancer Ther 2011;10(2):221-232.
58. Derin D, Soydinç HO, Guney N, Tas F, ÇamlIca H, DuranyIldIz D, Yasasever V, Topuz E. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer. Lung Cancer 2008;59(2):240-245.
59. Giaccone G, Zatloukal P, Roubec J, Floor K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A, Shamsili S. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin in patients with advanced refractory non-small-cell lung cancer. J Clin Oncol 2009;27(27):4481-4486.
60. Yamashita SI, Chujo M, Miyawaki M, Tokuishi K, Anami K, Yamamoto S, Kawahara K. Combination of p53AIP1 and survivin expression is a powerful prognostic marker in non-small cell lung cancer. J Exp Clin Canc Res 2009;(1):22.
61. Dai C-H, Li J, Shi S-B, Yu L-C, Ge L-P, Chen P. Survivin and Smac gene expressions but not livin are predictors of prognosis in non-small cell lung cancer patients treated with adjuvant chemotherapy following surgery. Jpn J Clin Oncol 2010;40(4):327-335.
62. Molina MA, Simonetti S, Quiroga V, Viteri S, Campelo RG, Sanchez J, Benlloch S, Aldeguer E, Taron M, Rosell R. Survivin and CrkL expression in erlotinib-treated non-small cell lung cancer (NSCLC) patients with EGFR mutations. J Clin Oncol 2010;28(15):e18063.
63. Grossi F, Spizzo R, Bordo D, Cacitti V, Valent F, Rossetto C, Follador A, Di Terlizzi S, Aita M, Morelli A, Fasola G, Consiglieri C, Ceschia T, Beltrami CA, Belvedere O. Prognostic stratification of stage IIIA pN2 non-small cell lung cancer by hierarchical clustering analysis of tissue microarray immunostaining data: An alpe adria thoracic oncology multidisciplinary group study (ATOM 014). J Thorac Oncol 2010;5(9):1354-1360.
64. Zhao H, Ren J, Zhuo X, Ye H, Zou J, Liu S. Prognostic significance of survivin and CD44v6 in laryngeal cancer surgical margins. J Cancer Res Clin Oncol 2008;134:1051-1058.
65. Chen J, Hu CF, Hou JH, Shao Q, Yan LX, Zhu XF, Zeng YX, Shao JY. Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma. J Transl Med 2010;30.
66. Kogiku M, Ohsawa I, Matsumoto K, Sugisaki Y, Takahashi H, Teramoto A, Ohta S. Prognosis of glioma patients by combined immunostaining for survivin, Ki-67 and epidermal growth factor receptor. J Clin Neurosci 2008;15(11):1198-1203.
67. Chen JH, Chen KY, Ma HI, Yu CP, Nieh S, Lee HS, Jin JS. Cortactin, fascin and survivin expression associated with clinicopathological parameters in brain gliosarcoma. Chin J Physiol 2010;53(4):234-244.
68. Yang X, Xiong G, Chen X, Xu X, Wang K, Fu Y, Yang K, Bai Y. Survivin expression in esophageal cancer: Correlation with p53 mutations and promoter polymorphism. Diseases of the Esophagus 2009;22(3):223-230.
69. Oluwadayo Oluwadara, Luca Giacomelli, Russell Christensen, George Kossan, Raisa Avezova, Chiappelli F. LCK, survivin and PI-3K in the molecular biomarker profiling of oral lichen planus and oral squamous cell carcinoma. Bioinformation 2009;4(6):249-257.
70. Preuss SF, Weinell A, Molitor M, Stenner M, Semrau R, Drebber U, Weissenborn SJ, Speel EJM, Wittekindt C, Guntinas-Lichius O, Hoffmann TK, Eslick GD, Klussmann JP. Nuclear survivin expression is associated with HPV-independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancer. Br J Cancer 2008;98(3):627-632.
71. Vermeij R, Daemen T, de Bock GH, de Graeff P, Leffers N, Lambeck A, ten Hoor KA, Hollema H, van der Zee AG, Nijman HW. Potential target antigens for a universal vaccine in epithelial ovarian cancer. Clin Dev Immunol 2010;2010, Article ID 891505, 8 pages, 2010. doi:10.1155/2010/891505.
72. Taylor DD, Atay S, Metzinger DS, Gercel-Taylor C. Characterization of humoral responses of ovarian cancer patients: Antibody subclasses and antigenic components. Gynecol Oncol 2010;116(2):213-221.
73. Engels K, Knauer SK, Loibl S, Fetz V, Harter P, Schweitzer A, Fisseler-Eckhoff A, Kommoss F, Hanker L, Nekljudova V, Hermanns I, Kleinert H, Mann W, du Bois A, Stauber RH. NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas. Cancer Res 2008;68(13):5159-5166.
74. Lin CK, Chao TK, Yu CP, Yu MH, Jin JS. The expression of six biomarkers in the four most common ovarian cancers: Correlation with clinicopathological parameters. APMIS 2009;117(3):162-175.
75. Basha R, Ingersoll SB, Sankpal UT, Ahmad S, Baker CH, Edwards JR, Holloway RW, Kaja S, Abdelrahim M. Tolfenamic acid inhibits ovarian cancer cell growth and decreases the expression of c-Met and survivin through suppressing specificity protein transcription factors. Gynecol Oncol 2011;122(1):163-170.
76. Shariat SF, Ashfaq R, Roehrborn CG, Slawin KM, Lotan Y. Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol 2005;174(5):2046-2050.
77. Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, Leibovich BC, Blute ML, Sebo TJ, Cheville JC, Parker AS, Kwon ED. Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res 2007;13(6):1749-1756.
78. Nazarian RM, Prieto VG, Elder DE, Duncan LM. Melanoma biomarker expression in melanocytic tumor progression: A tissue microarray study. J Cutan Pathol 2010;37 Suppl 1:41-47.
79. Trepiakas R, Berntsen A, Hadrup SR, Bjorn J, Geertsen PF, Straten PT, Andersen MH, Pedersen AE, Soleimani A, Lorentzen T, Johansen JS, Svane IM. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: Results from a phase I/II trial. Cytotherapy 2010;12(6):721-734.
80. Chiodino C, Cesinaro AM, Ottani D, Fantini F, Giannetti A, Trentini GP, Pincelli C. Communication: Expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin. J Invest Dermatol 1999;113(3):415-418.
81. Allen SM, Florell SR, Hanks AN, Alexander A, Diedrich MJ, Altieri DC, Grossman D. Survivin expression in mouse skin prevents papilloma regression and promotes chemical-induced tumor progression. Cancer Res 2003;63(3):567-572.
82. Aziz MH, Ghotra AS, Shukla Y, Ahmad N. Ultraviolet-B radiation causes an upregulation of survivin in human keratinocytes and mouse skin. Photochem Photobiol 2004;80(3):602-608.
83. Honma I, Kitamura H, Torigoe T, Takahashi A, Tanaka T, Sato E, Hirohashi Y, Masumori N, Tsukamoto T, Sato N. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer. Cancer Immunol Immunother 2009;58(11):1801-1807.
84. Wang YH, Chiou HY, Lin CT, Hsieh HY, Wu CC, Hsu CD, Shen CH. Association between survivin gene promoter-31 C/G polymorphism and urothelial carcinoma risk in Taiwanese population. Urology 2009;73(3):670-674.
85. Pollard C, Nitz M, Baras A, Williams P, Moskaluk C, Theodorescu D. Genoproteomic mining of urothelial cancer suggests γ-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy. Am J Pathol 2009;175(5):1824-1830.
86. Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R, Uenaka K, Callies S, Tamura T. Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011;68(2):505-511.
87. Baratti D, Kusamura S, Deraco M. Diffuse malignant peritoneal mesothelioma: Systematic review of clinical management and biological research. J Surg Oncol 2011;103(8):822-831.
88. Frei C, Opitz I, Soltermann A, Fischer B, Moura U, Rehrauer H, Weder W, Stahel R, Felley-Bosco E. Pleural mesothelioma side populations have a precursor phenotype. Carcinogenesis 2011;32(9):1324-1332.
89. Davidson B. New diagnostic and molecular characteristics of malignant mesothelioma. Ultrastruc Pathol 2008;32(6):227-240.
90. Shirai K, Suzuki Y, Oka K, Noda SE, Katoh H, Itoh J, Itoh H, Ishiuchi S, Sakurai H, Hasegawa M, Nakano T. Nuclear survivin expression predicts poorer prognosis in glioblastoma. J Neurooncol 2009;91(3):353-358.
91. Cheung CHA, Kanwar J, Krissansen GW. A cell-permeable dominant-negative Survivin protein as a tool to understand how survivin maintains tumour cell survival. Eur J Cancer Suppl 2006;4(12):149-149.
92. Baratchi S, Kanwar RK, Kanwar JR. Survivin mutant protects differentiated dopaminergic SK-N-SH cells against oxidative stress. PLoS ONE 2011;6(1):e15865.
93. Baratchi S, Kanwar RK, Kanwar JR. Novel survivin mutant protects differentiated SK-N-SH human neuroblastoma cells from activated T-cell neurotoxicity. J Neuroimmunol 2011;233(1-2):18-28.
94. Giannios J, Delis S, Barbunis V. Biologic anticancer activity of designed ankyrin repeat proteins (darpins) targeted against dnmt1 and conjugated to docetaxel leads to eradication of chemoresistant mutated squamous cell epsophageal cancer stem cells. Gut 2011;60(Suppl 1):A110.
95. Lin C-K, Chao T-K, Yu C-P, Yu M-H, Jin J-S. The expression of six biomarkers in the four most common ovarian cancers: Correlation with clinicopathological parameters. APMIS 2009;117(3):162-175.
96. Nowak-Markwitz E, Pula B, Szajnik M DP, Piotrowska A, Zabel M SM. Expression of survivin, SDF-1 and CXCR4 on tumor cells in ovarian cancer. Ginekol Pol 2010;81(9):674-677.
97. Wiechno PJ, Chlosta P, Smok-Kalwat J, Pikilel J, Henry DH, Christianson DF, Somer BG, Mellado B, Duran I, Castellano DE, Callies S, Andre V, Hurt K, Lahn MMF, Stockle M, Reuter C, Heinrich B. Interim results of a randomized phase II study with window-design to evaluate antitumor activity of the survivin antisense oligonucleotide (ASO) LY2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC). ASCO Meet Abstr 2011;29(15_suppl):4592.
98. Cheung CHA, Sun X, Kanwar J, Bai J-Z, Cheng L, Krissansen G. A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-alpha therapy. Cancer Cell Int 2010;10(1):36.
99. Trepiakas R, Berntsen A, Hadrup SR, Bjørn J, Geertsen PF, Straten PT, Andersen MH, Pedersen AE, Soleimani A, Lorentzen T, Johansen JS, Svane IM. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: Results from a phase I/II trial. Cytotherapy 2010;12(6):721-734.
100. Kanwar JR, Roy K, Kanwar RK. Chimeric aptamers in cancer cell-targeted drug delivery. Crit Rev Biochem Mol Biol 2011;46(6):459-477.
101. Gibert B, Hadchity E, Czekalla A, Aloy MT, Colas P, Rodriguez-Lafrasse C, Arrigo AP, Diaz-Latoud C. Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers. Oncogene 2011;30(34):3672-3681.
102. Kanwar JR, Kanwar RK, Mahidhara G, Cheung CHA. Cancer targeted nanoparticles specifically induce apoptosis in cancer cells and spare normal cells. Aust J Chem 2012;65(1):5-14.
103. Morrison DJ, Hogan LE, Condos G, Bhatla T, Germino N, Moskowitz NP, Lee L, Bhojwani D, Horton TM, Belitskaya-Levy I, Greenberger LM, Horak ID, Grupp SA, Teachey DT, Raetz EA, Carroll WL. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models. Leukemia 2011;26:271-279.